Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2011

View Archived Issues

Researchers uncover mechanism of action of epigenetic modifier UVI-5008

Nektar Therapeutics discloses novel opioid analgesic with low abuse potential

Results of phase II evaluation of evacetrapib presented

New biomarker identified in patients with myelodysplastic syndromes

Further clinical data on REGN-727 reported

Nerviano Medical Sciences presents preclinical findings on NMS-P948

AZT-2 enhances neurotransmission in preclinical models

REG2 Anticoagulation System evaluated in humans

Radikal Therapeutics presents new bifunctional PARP inhibitors

Novel mineralocorticoid receptor antagonists prepared by Pfizer

Sentinel Oncology synthesizes novel Chk1 inhibitors

Researchers at GlaxoSmithKline disclose new EZH2 inhibitors

Genentech and Gilead Sciences jointly prepare new BTK inhibitors

Sanofi recruits patients in phase I/II trial of SAR-113945

Bristol-Myers Squibb collaborates with Tibotec Pharmaceuticals on phase II HCV trial

Titan Pharmaceuticals reports FDA regulatory guidance for Probuphine NDA

Adventrx and FDA discuss development of ANX-188

Stellar Pharmaceuticals to acquire Tribute Pharmaceuticals

Bayer and Regeneron report integrated analysis of VIEW studies

Tissue Therapies enters partnerships for wound care product

GSK submits additional information to FDA for MenHibrix BLA

Cell Therapeutics provides update on MAA for Pixuvri

Kyowa Hakko Kirin launches new formulation of Nauzelin in Japan

Shire submits joint clinical trials proposal to confirm benefit of ProAmatine to FDA

Australian regulators to remove dextropropoxyphene-containing painkillers from the market

Amicus initiates phase II study of investigational chaperone with ERT in Pompe's disease

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...